|Bid||68.35 x 800|
|Ask||68.15 x 800|
|Day's Range||68.09 - 69.28|
|52 Week Range||39.37 - 76.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.11 (0.16%)|
|Ex-Dividend Date||Apr 30, 2021|
|1y Target Est||75.82|
Alcon’s Sue-Jean Lin Wins 2021 Dallas CIO of the Year
ALC earnings call for the period ending December 31, 2020.
Shares of Alcon (NYSE:ALC) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 8.89% over the past year to $0.41, which were in line with the estimate of $0.41. Revenue of $1,925,000,000 higher by 2.34% year over year, which beat the estimate of $1,890,000,000. Guidance Earnings guidance hasn't been issued by the company for now. View more earnings on ALC Revenue guidance hasn't been issued by the company for now. Technicals 52-week high: $76.26 Company's 52-week low was at $39.37 Price action over last quarter: Up 10.91% Company Profile Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with 41% of revenue in the U.S. market, and the firm has a strong presence in the European Union and Japan. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.